Prostate cancer hijacks amino acids to fuel cholesterol and therapy resistance
TL;DR
Weill Cornell researchers found that prostate tumors rewire amino acid metabolism to raise propionyl-CoA, which propionylates and stabilizes the SREBP2 transcription factor, keeping cholesterol production active even when hormone signaling is blocked. This supports androgen receptor activity and may drive resistance to therapies like enzalutamide; strategies that reduce isoleucine/valine intake or target the propionyl-CoA–SREBP2 axis could improve treatment responses.
- Study shows how prostate tumors rewire metabolism to resist therapy News-Medical
- Isoleucine and valine promote prostate cancer progression via propionyl-CoA-mediated cholesterol metabolism Nature
- Prostate Cancer Rewires Amino Acid Metabolism to Drive Treatment Resistance Inside Precision Medicine
- Isoleucine and Valine Fuel Prostate Cancer Progression by Altering Cholesterol Metabolism Bioengineer.org
- Prostate cancer hijacks amino acid metabolism to signal hormone therapy resistance EurekAlert!
Want the full story? Read the original reporting
Read on News-Medical